MiR-181a: A potential biomarker of acute muscle wasting following elective high-risk cardiothoracic surgery

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Bloch, Susannah A A ^a,b   Donaldson, Anna V J ^b   Lewis, Amy ^a   Banya, Winston A S ^b   Polkey, Michael I ^b   Griffiths, Mark J D ^a,b   Kemp, Paul R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 16; MICRORNA 181A; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN181 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; MALE; MORBIDITY; MUSCLE ATROPHY; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RECTUS FEMORIS MUSCLE; THORAX SURGERY; ACUTE DISEASE; BLOOD; CARDIOVASCULAR SURGERY; MIDDLE AGED; MUSCULAR ATROPHY; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ACUTE DISEASE; AGED; BIOMARKERS; CARDIOVASCULAR SURGICAL PROCEDURES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MUSCULAR ATROPHY; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THORACIC SURGICAL PROCEDURES;

EID: 84928034886     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0853-5     Document Type: Article

References (31)

1. Polkey MI, Moxham J. Clinical aspects of respiratory muscle dysfunction in the critically ill. Chest. 2001;119:926-39.
2. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10:931-41.
3. Tennila A, Salmi T, Pettila V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med. 2000;26:1360-3.
4. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310:1591-600.
5. De Jonghe B, Sharshar T, Lefaucheur J, Authier F, Durand-Zaleski I, Boussarsar M, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002;288:2859-67.
6. Fletcher S, Kennedy D, Ghosh I, Misra V, Kiff K, Coakley J, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med. 2003;31:1012-6.
7. Steiner MC, Roubenoff R, Tal-Singer R, Polkey MI. Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review. Thorax. 2012;67:1102-9.
8. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172-87.
9. Deddens JC, Colijn JM, Oerlemans MI, Pasterkamp G, Chamuleau SA, Doevendans PA, et al. Circulating MicroRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J Cardiovasc Transl Res. 2013;6:884-98.
10. De Guire V, Robitaille R, Tetreault N, Guerin R, Menard C, Bambace N, et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin Biochem. 2013;46:846-60.
11. Van Roosbroeck K, Pollet J, Calin GA. miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn. 2013;13:183-204.
12. Donaldson A, Natanek SA, Lewis A, Man WD, Hopkinson NS, Polkey MI, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax. 2013;68:1140-9.
13. Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax. 2012;67:26-34.
14. Chen JF, Callis TE, Wang DZ. microRNAs and muscle disorders. J Cell Sci. 2009;122:13-20.
15. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M, et al. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol. 2006;8:278-84.
16. Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, et al. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. Thorax. 2015;70(3):219-28. doi: 10.1136/thoraxjnl-2014-206225.
17. Bloch SA, Lee JY, Wort SJ, Polkey MI, Kemp PR, Griffiths MJ. Sustained elevation of circulating growth and differentiation factor-15 and a dynamic imbalance in mediators of muscle homeostasis are associated with the development of acute muscle wasting following cardiac surgery. Crit Care Med. 2013;41:982-9.
18. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9-13.
19. Seymour J, Ward K, Sidhu P, Puthucheary Z, Steier J, Jolley C, et al. Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD. Thorax. 2009;64:418-23.
20. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40(5):1115-22. doi: 10.1183/09031936.00170111.
21. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50:298-301.
22. Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37:S299-308.
23. Harris ML, Luo YM, Watson AC, Rafferty GF, Polkey MI, Green M, et al. Adductor pollicis twitch tension assessed by magnetic stimulation of the ulnar nerve. Am J Respir Crit Care Med. 2000;162:240-5.
24. Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie LX. Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects. Clin Chem Lab Med. 2012;50:1423-8.
25. Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010;391:73-7.
26. Hutchison ER, Kawamoto EM, Taub DD, Lal A, Abdelmohsen K, Zhang Y, et al. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia. 2013;61:1018-28.
27. Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol. 2010;109:635-42.
28. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531-43.
29. Sun X, Sit A, Feinberg MW. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc Med. 2014;24(3):105-12. doi:10.1016/j.tcm.2013.09.002.
30. Bloch S, Polkey MI, Griffiths M, Kemp P. Molecular mechanisms of intensive care unit- acquired weakness. Eur Respir J. 2012;39:1000-11.
31. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973-90.